LEXEO THERAPEUTICS INC
LXEONASDAQTrading Snapshot
- Day Range
- $3.16 – $3.38
- 52-Week Range
- $2.55 – $10.99
- Volume (shares)
- 247,794
- Avg Volume (shares)
- —
- Shares Outstanding
- 82.1M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -2.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +130.9%
LEXEO THERAPEUTICS INC
LXEO
StockOtter · stockotter.spaceAbout LEXEO THERAPEUTICS INC
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
Lexeo Therapeutics NASDAQ: LXEO outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich's ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Charda
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
Lexeo Therapeutics NASDAQ: LXEO outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regul
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an ed
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will p
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI nat